6WXL
 
 | |
8TMY
 | |
8TMZ
 | |
6DL8
 | |
4ODS
 | |
8F2J
 | |
8F2X
 | |
6UUM
 | | Crystal structure of antibody 438-B11 DSS mutant (Cys98A-Cys100aA) | | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, ACETATE ION, B11 DSS Fab Heavy Chain, ... | | Authors: | Kumar, S, Wilson, I.A. | | Deposit date: | 2019-10-30 | | Release date: | 2020-09-23 | | Last modified: | 2023-10-11 | | Method: | X-RAY DIFFRACTION (2.1 Å) | | Cite: | A V H 1-69 antibody lineage from an infected Chinese donor potently neutralizes HIV-1 by targeting the V3 glycan supersite.
Sci Adv, 6, 2020
|
|
4ISV
 | | Crystal structure of the Fab FRAGMENT OF 1C2, A MONOCLONAL ANTIBODY SPECIFIC FOR POLY-GLUTAMINE | | Descriptor: | 1C2 FAB HEAVY CHAIN, 1C2 FAB LIGHT CHAIN | | Authors: | Klein, F.A.C, Zeder-Lutz, G, Cousido-Siah, A, Mitschler, A, Katz, A, Eberling, P, Mandel, J.L, Podjarny, A, Trottier, Y. | | Deposit date: | 2013-01-17 | | Release date: | 2013-07-03 | | Last modified: | 2017-11-15 | | Method: | X-RAY DIFFRACTION (1.497 Å) | | Cite: | Linear and extended: a common polyglutamine conformation recognized by the three antibodies MW1, 1C2 and 3B5H10.
Hum.Mol.Genet., 22, 2013
|
|
6UUL
 | | Crystal structure of broad and potent HIV-1 neutralizing antibody 438-D5 | | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-[alpha-L-fucopyranose-(1-6)]2-acetamido-2-deoxy-beta-D-glucopyranose, D5 Fab Heavy Chain, ... | | Authors: | Kumar, S, Wilson, I.A. | | Deposit date: | 2019-10-30 | | Release date: | 2020-09-23 | | Last modified: | 2023-10-11 | | Method: | X-RAY DIFFRACTION (2.06 Å) | | Cite: | A V H 1-69 antibody lineage from an infected Chinese donor potently neutralizes HIV-1 by targeting the V3 glycan supersite.
Sci Adv, 6, 2020
|
|
7EO0
 | | FOOT AND MOUTH DISEASE VIRUS O/TIBET/99-BOUND THE SINGLE CHAIN FRAGMEN ANTIBODY C4 | | Descriptor: | Ig heavy chain variable region, Ig lamda chain variable region, O/TIBET/99 VP1, ... | | Authors: | He, Y, Li, K. | | Deposit date: | 2021-04-21 | | Release date: | 2021-08-18 | | Last modified: | 2022-02-23 | | Method: | ELECTRON MICROSCOPY (3.75 Å) | | Cite: | Two Cross-Protective Antigen Sites on Foot-and-Mouth Disease Virus Serotype O Structurally Revealed by Broadly Neutralizing Antibodies from Cattle.
J.Virol., 95, 2021
|
|
6UUH
 | |
4JJ5
 | | CRYSTAL STRUCTURE OF THE Fab FRAGMENT OF 1C2, A MONOCLONAL ANTIBODY SPECIFIC for POLY-GLUTAMINE | | Descriptor: | 1C2 FAB HEAVY CHAIN, 1C2 FAB LIGHT CHAIN | | Authors: | Klein, F.A.C, Zeder-Lutz, G, Cousido-Siah, A, Mitschler, A, Katz, A, Eberling, P, Mandel, J.L, Podjarny, A, Trottier, Y. | | Deposit date: | 2013-03-07 | | Release date: | 2013-07-03 | | Last modified: | 2023-09-20 | | Method: | X-RAY DIFFRACTION (2.445 Å) | | Cite: | Linear and extended: a common polyglutamine conformation recognized by the three antibodies MW1, 1C2 and 3B5H10.
Hum.Mol.Genet., 22, 2013
|
|
8DZH
 | |
8SO3
 | | CryoEM structure of a therapeutic antibody (favezelimab) bound to human LAG3 | | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, Lymphocyte activation gene 3 protein, favezelimab Fab heavy chain, ... | | Authors: | Mishra, A.K, Shahid, S, Karade, S.S, Mariuzza, R.A. | | Deposit date: | 2023-04-28 | | Release date: | 2023-09-06 | | Last modified: | 2023-10-18 | | Method: | ELECTRON MICROSCOPY (3.61 Å) | | Cite: | CryoEM structure of a therapeutic antibody (favezelimab) bound to human LAG3 determined using a bivalent Fab as fiducial marker.
Structure, 31, 2023
|
|
8SR0
 | | CryoEM structure of a therapeutic antibody (favezelimab) bound to human LAG3 local refined | | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, Lymphocyte activation gene 3 protein, favezelimab Fab heavy chain, ... | | Authors: | Mishra, A.K, Shahid, S, Karade, S.S, Mariuzza, R.A. | | Deposit date: | 2023-05-05 | | Release date: | 2023-09-06 | | Last modified: | 2023-10-18 | | Method: | ELECTRON MICROSCOPY (3.53 Å) | | Cite: | CryoEM structure of a therapeutic antibody (favezelimab) bound to human LAG3 determined using a bivalent Fab as fiducial marker.
Structure, 31, 2023
|
|
5VZ1
 | | Crystal structure of the Apo Antibody fragment (Fab) raised against C-terminal domain of Ebola nucleoprotein (EBOV, TAFV, BDBV strains) | | Descriptor: | Apo Antibody Fab Heavy Chain, Apo Antibody Fab Light Chain, ZINC ION | | Authors: | Radwanska, M.J, Derewenda, U, Kossiakoff, A, Derewenda, Z.S. | | Deposit date: | 2017-05-26 | | Release date: | 2018-06-27 | | Last modified: | 2023-10-04 | | Method: | X-RAY DIFFRACTION (2.112 Å) | | Cite: | Crystal structure of the Apo Antibody fragment (Fab) raised against C-terminal domain of Ebola nucleoprotein (EBOV, TAFV, BDBV strains)
To Be Published
|
|
8UT5
 | | CryoEM structure of A/Michigan/45/2015 H1 in complex with flu HA central stem VH1-18 antibody UCA6_N55T | | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, Hemagglutinin HA1 chain, Hemagglutinin HA2 chain, ... | | Authors: | Huang, J, Han, J, Ward, A.B. | | Deposit date: | 2023-10-30 | | Release date: | 2024-05-08 | | Last modified: | 2024-05-29 | | Method: | ELECTRON MICROSCOPY (3.5 Å) | | Cite: | Eliciting a single amino acid change by vaccination generates antibody protection against group 1 and group 2 influenza A viruses.
Immunity, 57, 2024
|
|
8UT4
 | | CryoEM structure of A/Michigan/45/2015 H1 in complex with flu HA central stem VH1-18 antibody 09-1B12 | | Descriptor: | 09-1B12 HC Fv, 09-1B12 LC Fv, 2-acetamido-2-deoxy-beta-D-glucopyranose, ... | | Authors: | Huang, J, Han, J, Ward, A.B. | | Deposit date: | 2023-10-30 | | Release date: | 2024-05-08 | | Last modified: | 2024-05-29 | | Method: | ELECTRON MICROSCOPY (3.3 Å) | | Cite: | Eliciting a single amino acid change by vaccination generates antibody protection against group 1 and group 2 influenza A viruses.
Immunity, 57, 2024
|
|
6BIT
 | | SIRPalpha antibody complex | | Descriptor: | KWAR23 Fab heavy chain, KWAR23 Fab light chain, Tyrosine-protein phosphatase non-receptor type substrate 1 | | Authors: | Ring, N.G, Herndler-Brandstetter, D, Weiskopf, K, Shan, L, Volkmer, J.P, George, B.M, Lietzenmayer, M, McKenna, K.M, Naik, T.J, McCarty, A, Zheng, Y, Ring, A.M, Flavell, R.A, Weissman, I.L. | | Deposit date: | 2017-11-03 | | Release date: | 2017-12-06 | | Last modified: | 2019-11-20 | | Method: | X-RAY DIFFRACTION (2.191 Å) | | Cite: | Anti-SIRP alpha antibody immunotherapy enhances neutrophil and macrophage antitumor activity.
Proc. Natl. Acad. Sci. U.S.A., 114, 2017
|
|
6BSP
 | | High-Resolution Structure Analysis of Antibody V5 and U4 Conformational Epitope on Human Papillomavirus 16 | | Descriptor: | Major capsid protein L1, U4 Heavy chain, U4 Light chain | | Authors: | Guan, J, Bywaters, S.M, Brendle, S.A, Ashley, R.E, Makhov, A.M, Conway, J.F, Christenson, N.D, Hafenstein, S. | | Deposit date: | 2017-12-04 | | Release date: | 2018-02-14 | | Last modified: | 2018-10-24 | | Method: | ELECTRON MICROSCOPY (4.7 Å) | | Cite: | High-Resolution Structure Analysis of Antibody V5 and U4 Conformational Epitopes on Human Papillomavirus 16.
Viruses, 9, 2017
|
|
5W42
 | |
8DZI
 | |
8UT3
 | | CryoEM structure of A/Perth/16/2009 H3 in complex with flu HA central stem VH1-18 antibody UCA6 | | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, Hemagglutinin, ... | | Authors: | Huang, J, Han, J, Ward, A.B. | | Deposit date: | 2023-10-30 | | Release date: | 2024-05-08 | | Last modified: | 2024-05-29 | | Method: | ELECTRON MICROSCOPY (2.8 Å) | | Cite: | Eliciting a single amino acid change by vaccination generates antibody protection against group 1 and group 2 influenza A viruses.
Immunity, 57, 2024
|
|
7EAN
 | | immune complex of SARS-CoV-2 RBD and cross-neutralizing antibody 6D6 | | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, Heavy chain of SARS-CoV-2 cross-neutralizing mAb 6D6, Light chain of SARS-CoV-2 cross-neutralizing mAb 6D6, ... | | Authors: | Li, T.T, Gu, Y, Li, S.W. | | Deposit date: | 2021-03-07 | | Release date: | 2021-03-31 | | Last modified: | 2023-11-29 | | Method: | X-RAY DIFFRACTION (1.91 Å) | | Cite: | Cross-neutralizing antibodies bind a SARS-CoV-2 cryptic site and resist circulating variants.
Nat Commun, 12, 2021
|
|
